Drug Profile
ANV 201
Alternative Names: ANV-201Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Anvil Biosciences
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuromyelitis optica
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Neuromyelitis optica in USA (unspecified route) (Anvil Biosciences website, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Neuromyelitis-optica in USA
- 11 Aug 2016 Preclinical trials in Neuromyelitis optica in USA (unspecified route)